Replies to post #169083 on Cytodyn Inc (CYDY)

[stockorus]

[A quick "best guess" calculation I did just now (not checking this thoroughly) shows that most likely:

Mortality between Day 1 and Day 7:

LL+SOC: 2 deaths out of 43 patients (4.65%)
Placebo+SOC: 4 deaths out of 19 patients (21.05%)

Mortality reduction: (21.05-4.65)/21.05 = 77.9% ]

Could also be (between Day 1 and Day 7):

LL+SOC: 1 death out of 43 (2.33%)
Placebo+SOC: 2 deaths out of 19 (10.53%)

Mortality reduction: (10.53-2.33)/10.53 = 77.87%

As I recall, this sort of multiple possibility situation did not happen when I calculated for the 14 day case.

[DonDonDonDon]

LL+SOC: 2 deaths out of 43 patients (4.65%)
Placebo+SOC: 5 deaths out of 19 patients (26.32%)

Note (26.32-4.65)/26.32 = 82.33 % mortality reduction.

There is a good chance your calculations are correct. My only reservation is that they are now showing the 78% and 82% numbers in the same chart as the 31% number at 28 days. We know that efficacy is 24% at 28 days. By dividing the difference (8.9%) by the mortality in the leronlimab arm (27.9%) instead of the placebo arm (36.84%), it changes the relative efficacy percentage from 24% to 31%. If the chart is consistent, then the 82% is likely around 63% in reality. Granted, this is CytoDyn so maybe the chart doesn't use a consistent method to calculate the different percentages at 7, 14, 21, and 28 days. It sure would be nice if CytoDyn would release the raw data. Clearly, they are hiding something.